ANI Pharma (ANIP) Misses Q1 EPS by 31c, Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q1 EPS of ($0.12), $0.31 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $64.5 million versus the consensus estimate of $68.03 million.

GUIDANCE:

ANI Pharma sees FY2022 EPS of $1.34-$1.62, versus the consensus of $1.15. ANI Pharma sees FY2022 revenue of $295-315 million, versus the consensus of $292.8 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance